Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name	Generic Name	Therapeutic Area	Recommendation Type Sort ascending	Project Status	Date Submission Received	Date Recommendation Issued
Revolade	Eltrombopag olamine	Chronic immune thrombocytopenic purpura	Do not list	Complete	Apr 26, 2011	Oct 24, 2011
Brilinta	Ticagrelor	Acute coronary syndromes	Do not list	Complete	Jun 1, 2011	Dec 16, 2011
BuTrans	Buprenorphine transdermal patch	Pain, moderate intensity persistent pain	Do not list	Complete	May 9, 2011	Sep 28, 2011
Iressa	Gefitinib	Cancer, Lung , non-small cell	Do not list	Complete	Dec 22, 2003	Jun 23, 2004
Evra	Norgelestromin/ethinyl estradiol	Contraceptive, patch	Do not list	Complete	Dec 19, 2003	Jun 23, 2004
Replagal	Agalsidase alfa	Fabry Disease	Do not list	Complete	Feb 19, 2004	Nov 24, 2004
Fabrazyme	Agalsidase beta	Fabry Disease	Do not list	Complete	Feb 24, 2004	Nov 24, 2004
Viread	Tenofovir disoproxil fumarate	HIV infection	Do not list	Complete	Feb 23, 2004	Aug 25, 2004
Adderall XR	Mixed amphetamine salts	Attention deficit hyperactivity disorder	Do not list	Complete	Apr 13, 2004	Nov 24, 2004
Zavesca	Miglustat	Gaucher disease	Do not list	Complete	May 13, 2004	Nov 24, 2004

Last Updated : May 7, 2024